Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection

Tongji Hospital

Status: Begins enrollment this month

Conditions: Lobectomy

Treatments: Drug: Tegileridine; Drug: Sufentanil; Procedure: Intercostal Nerve Block

Study type: Interventional

Funder types: Other

Identifiers

NCT07386626

TITL

Details and patient eligibility

About

Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. Thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Full description

Combining tegileridine PCIA with ICNB targeting peripheral nerves, may constitute an ideal analgesic model with complementary advantages. ICNB provides rapid and precise incision analgesia in the early postoperative period, effectively blocking the transmission of peripheral nociceptive stimuli to the central nervous system. Tizanidine PCIA, on the other hand, enhances the function of the endogenous descending pain suppression system through its central G protein pathway activation, covering the pain period after the effect of ICNB wears off and components such as visceral referred pain. At the same time, it can effectively reduce side effects such as respiratory depression and nausea/vomiting, thus potentially achieving the analgesic goal of "early pain relief, stable throughout the process, and rapid recovery," and may have a positive impact on reducing CPSP.

Enrollment: 118 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age range: 18 to 75 years old;
• Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
• ASA classification levels I-III;
• BMI 18 ~ 30 kg/m2。
• Voluntarily participate and sign an informed consent form.

Exclusion criteria

• Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
• Pregnant or lactating women;
• Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
• Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
• Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
• Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

118 participants in 2 patient groups

sufentanil group

Active Comparator group

Description:

Administer 0.15 μg/kg (maximum 10 μg) of sufentanil intravenously 40 minutes before the end of surgery, followed by the connection of a sufentanil patient-controlled intravenous analgesia (PCIA)

Treatment:

Procedure: Intercostal Nerve Block

Drug: Sufentanil

Tegileridine group

Experimental group

Description:

Administer 0.015 mg/kg (maximum 1mg) of tegileridine intravenously 40 minutes before the end of surgery, followed by the connection of a tegileridine patient-controlled intravenous analgesia (PCIA)

Treatment:

Procedure: Intercostal Nerve Block

Drug: Tegileridine